Standard Operating Procedure for Medical Store

STANDARD OPERATING PROCEDURE: PHARMACEUTICAL RETAIL & CLINICAL DISPENSING OPERATIONS

Document ID: SOP-TR-MED-409
Effective Date: October 24, 2023
Version: 4.2
Review Cadence: Semi-Annual
Target Audience: Licensed Pharmacists, Pharmacy Technicians, Inventory Control Specialists, Quality Assurance Officers, and Front-of-House Operations Staff.

---

1. EXECUTIVE SUMMARY & SCOPE

This Standard Operating Procedure (SOP) defines the institutional requirements for the receipt, storage, inventory control, compounding, dispensing, and reverse distribution of pharmaceutical products within all Template Registry-affiliated medical stores and clinical dispensaries.

The scope of this document encompasses all cold-chain logistics, controlled substance management, patient safety verifications, and adverse event reporting. Operations governed by this SOP must strictly adhere to Good Pharmacy Practice (GPP), United States Pharmacopeia (USP) standards—specifically USP <659> (Packaging and Storage Requirements), USP <795> (Nonsterile Compounding), and USP <800> (Handling Hazardous Drugs)—alongside local and federal Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) regulatory frameworks.

---

2. PREREQUISITES & TOOL REQUIREMENTS

Personnel and facility infrastructure must meet the following mandatory criteria prior to initiating operational workflows:

• Licensing & Certifications:
  • State-licensed Pharmacist-in-Charge (PIC) on active duty during all operational hours.
  • Registered Pharmacy Technicians with active state certifications (PTCB or equivalent).
  • Current DEA registration for controlled substance handling (Schedules II–V).
• Infrastructure & Environmental Controls:
  • Continuous Temperature Monitoring System (CTMS) equipped with NIST-traceable sensors and automated SMS/email escalation alarms.
  • Class II, Type A2 Biological Safety Cabinet (BSC) or Laminar Flow Hood (certified semi-annually).
  • Dedicated DEA-compliant Class V-rated steel safe bolted to the structural floor/wall for Schedule II narcotics storage.
• Software Systems:
  • Enterprise Pharmacy Management System (e.g., Epic Beacon, PioneerRx, or Cerner Millennium) with active role-based access controls.
  • Real-time electronic prescription clearinghouses (SureScripts network).
• Personal Protective Equipment (PPE):
  • ISO Class 4/5 compatible nitrile gloves (powder-free, low-allergen).
  • Disposable low-lint lab coats or medical scrubs.
  • ASTM F2100 Level 3 procedural face masks and eye protection (goggles/face shields) for hazardous drug handling under USP <800>.

---

3. ROLES & RESPONSIBILITIES (RACI MATRIX)

Legend: Responsible, Accountable, Consulted, **Informed***

---

4. STEP-BY-STEP OPERATIONAL PROCEDURE

Phase 1: Receiving, Cold-Chain Verification, and Inventory Intake

• Inspect incoming freight exterior packaging for signs of tampering, crushing, or temperature indicator activation (e.g., Timestrip or delta-T indicators).
• Transfer all cold-chain products (2°C to 8°C) immediately into pharmaceutical-grade refrigeration units upon unboxing.
• Log lot numbers, National Drug Codes (NDCs), expiration dates, and quantities into the Enterprise Pharmacy Management System.
• Separate and tag any compromised, short-dated (< 90 days), or recalled stock, placing them in the designated quarantine bin.
• Verify DEA Form 222 documentation line-by-line for any incoming Schedule II controlled substances prior to safe placement.

Phase 2: Prescriptive Screening and Utilization Review

• Receive electronic or physical prescriptions and verify legal authenticity, DEA number validity, and prescriber state licensure.
• Cross-reference patient profile for documented drug allergies, cross-sensitivities, chronic kidney disease (eGFR thresholds), and hepatic impairment.
• Perform Drug Utilization Review (DUR) screening for clinically significant drug-drug interactions, contraindications, and therapeutic duplications.
• Contact prescribing practitioner via secure channel to resolve clarification queries (e.g., ambiguous SIG, missing dosage form); document interventions in the patient profile.

Phase 3: Dispensing, Compounding, and Final Verification

• Generate prescription label from the master system, confirming patient identifiers (Full Name, Date of Birth, Medical Record Number).
• Retrieve stock bottle, scanning the barcode to verify NDC match against the electronic queue.
• Execute pill counting via clean, calibrated pharmaceutical tray and spatulas; utilize automated tablet counters where applicable.
• Execute compounding protocols (if applicable) under USP <795> or <800> containment guidelines, recording all weights, volumes, and lot numbers on the compounding worksheet.
• Present completed product, original stock bottle, dispensed vial, and verified prescription to the licensed Pharmacist for the Final Check (visual inspection for particulate matter, correct strength, formulation, and labeling).

Phase 4: Patient Counseling and Dispensation

• Confirm patient identity via two unique identifiers (Government-issued photo ID and DOB).
• Provide mandatory offer for face-to-face or telehealth clinical consultation administered exclusively by a licensed Pharmacist.
• Counsel patient on indication, correct administration technique, side-effect profile, storage conditions, and missed-dose protocols.
• Secure electronic or physical signature of receipt, ensuring HIPAA compliance and data privacy protocols.

Phase 5: End-of-Day Reconciliation and Environmental Audit

• Perform daily perpetual inventory cycle count for high-risk medications and all Schedule II controlled substances.
• Record high and low temperature extremes for all refrigerators, freezers, and ambient pharmacy storage zones.
• Run end-of-day electronic backup protocols for all dispensing databases and transaction logs.
• Secure all physical security perimeters, arm the biometric/electronic intrusion detection system, and ensure physical safes are double-locked.

---

5. QUALITY ASSURANCE & VERIFICATION CRITERIA

Medical store operations must continuously meet the following benchmark thresholds to maintain institutional accreditation:

• Dispensing Accuracy Rate: Target metric of 99.99%. Zero tolerance for Class I dispensing errors (wrong drug, wrong strength, wrong patient).
• Cold-Chain Integrity: Storage units must maintain strict nominal temperatures (Refrigeration: 2°C to 8°C; Freezer: -25°C to -10°C; Ambient Room Temp: 20°C to 25°C with excursions permitted between 15°C and 30°C). Any excursion > 15 minutes requires immediate quarantine of affected stock.
• Controlled Substance Discrepancy Thresholds: Zero-variance policy. Any discrepancy between perpetual inventory and physical count requires initiation of an immediate internal investigation and potential filing of DEA Form 106 within 24 hours.
• Audit Cadence: Monthly internal quality assurance audits conducted by the QA Officer covering sanitation, documentation, expired drug management, and USP compliance.

---

6. PRACTICAL TROUBLESHOOTING SCENARIOS

Scenario A: Refrigerator Temperature Excursion (Spike above 8°C or Drop below 2°C)

• Immediate Symptom: CTMS audible alarm activates, indicating storage unit internal temperature has drifted outside the 2°C–8°C window for > 15 minutes.
• Corrective Action Protocol:
  1. Mute the alarm and immediately transfer all sensitive biologicals and cold-chain stock to a verified secondary back-up refrigerator or cooler packed with qualified coolant bricks.
  2. Place a physical warning tag on the compromised unit: "DO NOT USE - TEMPERATURE EXCURSION PENDING INVESTIGATION."
  3. Download the data logger temperature history file to determine exact duration and peak/trough temperatures.
  4. Contact respective pharmaceutical manufacturers with stability data requests using the recorded excursion duration.
  5. If stability is unverified or excursions exceed manufacturer thresholds, quarantine and document stock for destruction. Log incident in the Corrective and Preventive Action (CAPA) system.

Scenario B: Controlled Substance Count Discrepancy During Perpetual Inventory

• Immediate Symptom: Physical count of a Schedule II narcotic (e.g., Oxycodone 10mg tablets) yields a lower quantity than the perpetual log in the electronic management system.
• Corrective Action Protocol:
  1. Halt all dispensing activity for the affected National Drug Code (NDC) immediately.
  2. Perform an immediate re-count of the specific bin and check surrounding safe shelves for dropped or misplaced stock.
  3. Review all transaction logs, physical prescription hard copies, and electronic dispensation records for the preceding 72 hours to identify miscounts, unrecorded returns, or transcription errors.
  4. If the discrepancy remains unresolved after a comprehensive audit, notify the Pharmacist-in-Chief and Compliance Officer instantly.
  5. Execute mandatory formal internal inquiry and, if theft or significant unexplained loss is suspected, file DEA Form 106 within the statutory 24-hour window, concurrently notifying local law enforcement.

Scenario C: Receipt of Damaged or Suspect Counterfeit Medication Freight

• Immediate Symptom: Delivery box contains broken vials, punctured blister packs, or packaging exhibiting irregular security seals, spelling errors, or atypical fonts.
• Corrective Action Protocol:
  1. Quarantine the entire delivery shipment in the designated secure returns bin away from operational stock.
  2. Do not unpack or process the inbound invoice in the Enterprise Management System.
  3. Photograph the external packaging, shipping labels, and internal compromised stock from multiple angles.
  4. Contact the primary wholesale distributor's customer service and compliance departments immediately to initiate a Return Goods Authorization (RGA) and product replacement.
  5. Submit a formal MedWatch report to the FDA (Form 3500) if counterfeit characteristics or adulteration are positively identified.